Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
54.92
-0.04 (-0.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,874,993
Open
55.24
Bid (Size)
54.92 (3)
Ask (Size)
54.94 (17)
Prev. Close
54.96
Today's Range
54.88 - 55.50
52wk Range
42.63 - 58.97
Shares Outstanding
1,250,690,553
Dividend Yield
3.47%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
October 11, 2024
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...
Via
Benzinga
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
October 10, 2024
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.
Via
Benzinga
Performance
YTD
+9.84%
+9.84%
1 Month
-3.87%
-3.87%
3 Month
+9.51%
+9.51%
6 Month
+18.77%
+18.77%
1 Year
+0.51%
+0.51%
More News
Read More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
Via
Benzinga
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
October 07, 2024
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
October 04, 2024
Via
Benzinga
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
October 03, 2024
Via
Chartmill
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
October 04, 2024
Via
Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
Via
Benzinga
Exposures
Product Safety
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Week In Review: Zenas Raises $259 Million In IPO
September 28, 2024
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
September 27, 2024
Via
Benzinga
Exposures
Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
September 27, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
September 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
September 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
Via
Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Via
Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Via
Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Via
MarketBeat
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
September 23, 2024
Via
Benzinga
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
September 23, 2024
Via
Benzinga
Exposures
Product Safety
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
September 20, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
September 20, 2024
Via
Benzinga
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
September 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
Via
Benzinga
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.